The prices of Carbidopa experienced a global downturn during December, reversing the upward trend of the previous month. This decline was largely driven by subdued demand from the pharmaceutical and healthcare sectors, alongside an abundant market supply. Moreover, year-end inventory clearance efforts played a key role, as suppliers and distributors aimed to liquidate older stock to prepare for new shipments at the start of the year. These factors collectively contributed to a more competitive market, intensifying downward pressure on Carbidopa prices.
In China, the decline in Carbidopa prices was influenced by additional factors, particularly the country’s softening economic conditions. In December xxxx, China&#xx;s official National Bureau of Statistics (NBS) Manufacturing PMI unexpectedly fell to xx.x, indicating a slowdown after a period of growth. While the index remained above the neutral xx threshold, signaling slight expansion, the slower pace of factory output—growing at its weakest rate in four...
